Roche to buy US biotech firm 89bio
Digest more
Stocktwits on MSN
89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious
Wolfe Research’s Andy Chen cut his rating on 89bio to 'Peer Perform' from 'Outperform' and did not assign a price target ...
Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, ...
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Seven equities ...
Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday. Bio-Rad Laboratories reported quarterly earnings of $2.61 per share which beat the ...
The drug-testing system screens fingerprint sweat for recent use of drugs, returning results in under ten minutes, the New York company said. Intelligent Bio said it is currently evaluating the FDA's ...
Novartis said Tuesday it is buying Tourmaline Bio for $1.4 billion in a deal that gives the Swiss pharma giant access to the ...
Nuvation Bio Inc. (NYSE: NUVB) is one of the best healthcare penny stocks to buy now. On September 7, the company delivered ...
Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along ...
GRI Bio stock surged with 6.9M shares traded, far exceeding its 17.35K average volume, per Benzinga Pro data. Interim Phase 2a results showed GRI-0621 was safe and well-tolerated in 12 patients, ...
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback